Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...
Great. Can everyone hear me? Can everyone hear us? Okay. Fantastic. Welcome, everyone. It's great to have you. Welcome, Gerald Herman, CFO of Bruker. I'm Aisyah Noor, European medtech analyst with ...
Bruker Corporation (Nasdaq: BRKR) today announced several significant European orders for high-performance magnetic resonance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback